Table 2.
Relation between adipokines and presence of the metabolic syndrome.
| Model | Adipsin | Chemerin | MCP-1 | MIF | NGF | Resistin | SAA1 | Adiponectin | Leptin | PAI-1 | HGF |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 0.96 | 0.91 | 1.08 | 1.05 | 1.12 | 0.85* | 0.98 | 0.72* | 1.21* | 0.94 | 1.20* |
| (0.85–1.09) | (0.80–1.04) | (0.95–1.23) | (0.92–1.19) | (0.98–1.27) | (0.75–0.97) | (0.86–1.11) | (0.63–0.83) | (1.06–1.38) | (0.83–1.08) | (1.05–1.38) | |
| II | 0.96 | 0.91 | 1.08 | 1.06 | 1.12 | 0.85* | 0.98 | 0.73* | 1.26* | 0.94 | 1.21* |
| (0.85–1.09) | (0.80–1.03) | (0.95–1.23) | (0.93–1.21) | (0.99–1.28) | (0.74–0.97) | (0.86–1.12) | (0.64–0.83) | (1.10–1.45) | (0.82–1.07) | (1.06–1.38) | |
| III | 0.85* | 0.99 | 1.06 | 0.98 | 1.04 | 0.85* | 1.11 | 0.82* | 1.14 | 1.04 | 1.08 |
| (0.74–0.98) | (0.86–1.14) | (0.92–1.23) | (0.85–1.13) | (0.90–1.19) | (0.73–0.98) | (0.96–1.29) | (0.71–0.96) | (0.98–1.34) | (0.90–1.20) | (0.93–1.25) |
Data are presented as odds ratios (ORs) with 95% confidence intervals (CIs) per 1 SD increase in adipokine concentrations. *P < 0.05.
MCP-1: monocyte chemoattractant protein 1; NGF: nerve growth factor; HGF: hepatic growth factor; PAI-1: plasminogen activator inhibitor 1; MIF: migration inhibitory factor; SAA1: serum amyloid A1; model I: crude model; model II: adjusted for age and gender; model III: additionally adjusted for visceral adipose tissue.